Skip to main content
Premium Trial:

Request an Annual Quote

EraGen, Emory to Develop Genotyping System to Combat HIV Drug Resistance

NEW YORK, March 23 (GenomeWeb News) - EraGen Biosciences said yesterday that it has entered into a collaborative agreement with Emory University to develop a genotyping system to detect drug-resistant HIV variants.

The project, supported by a $350,000 Small Business Technology Transfer grant from the National Institutes of Health, will develop a system to detect HIV mutations at an early stage, allowing physicians to optimize treatment before the virus is fully drug-resistant, EraGen said.

EraGen will provide Emory with its EraGen Real-Time PCR Assay, an RT-PCR method to detect and quantitate mixed populations of closely related viral sequences. According to EraGen, the method is able to detect one copy of mutant per 10,000 wild-type RNA copies in a reaction containing 15 million total target molecules.

The company said it plans to optimize the system to detect and quantitate 17 antiretroviral-resistant HIV mutations, which confer resistance to nucleoside inhibitors of reverse transcriptase, non-nucleoside RT inhibitors, and protease inhibitors.

EraGen said it would build on prototype systems it has already developed for quantitative resistance screening to the HIV therapeutics Viread, Emtriva, and Comitia.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.